Drugs like Semaglutide and Liraglutide exploded into the spotlight for one reason: weight loss.
But scientists keep noticing something weird.
People taking these medications seem to lose interest in… other things too.
Alcohol.
Nicotine.
Even opioids.
So researchers asked a simple question:
Are GLP-1 drugs quietly reducing addiction risk?
A massive new study suggests the answer might be yes.
The Study: Over 600,000 People
Researchers dug into healthcare records from the United States Department of Veterans Affairs.
Total participants: 606,434 patients with type 2 diabetes.
They compared two common diabetes drug classes:
• GLP-1 receptor agonists (like semaglutide)
• SGLT-2 inhibitors (another diabetes drug class)
The second group acts mostly in the kidneys and doesn’t affect the brain’s reward system — making it a useful comparison.
Researchers then tracked patients for three years.
They wanted to see:
- Who developed new substance use disorders
- What happened to people who already had addiction
The Results: Fewer New Addictions
People taking GLP-1 drugs had lower risk of developing multiple substance use disorders, including:
• Alcohol use disorder
• Cannabis use disorder
• Cocaine use disorder
• Nicotine use disorder
• Opioid use disorder
Not just one category — almost the entire addiction spectrum.
That’s unusual.
Most drugs only affect one substance pathway.
It Didn’t Stop There
Researchers also looked at people who already had addiction.
Among these patients, GLP-1 medications were linked to lower risk of:
• Drug overdoses
• Emergency room visits related to substance use
• Hospitalizations
• Death related to substance use
• Suicidal thoughts or attempts
In other words:
The drugs didn’t just correlate with less addiction developing.
They also correlated with less harm in people already struggling with addiction.
Why Would a Diabetes Drug Affect Addiction?
The answer likely lives in the brain.
GLP-1 isn’t just a metabolic hormone — it’s also active in reward circuits.
These drugs cross the blood-brain barrier within minutes.
Once in the brain, they influence areas tied to:
• Motivation
• Reward
• Impulse control
• Dopamine signaling
That’s the same circuitry involved in addiction.
Researchers think GLP-1 drugs may dampen the reward response that addictive substances normally trigger.
Less reward → less craving → less use.
Scientists Have Seen Hints of This Before
Smaller studies have already shown:
• Reduced alcohol cravings
• Lower alcohol consumption
• Possible improvements in smoking cessation
But the results were mixed and the trials were small.
This new analysis is different because it looks across multiple addictions at once in a very large population.
The Suicidal Ideation Question
At one point regulators worried these drugs might increase suicidal thoughts.
But this study actually found the opposite.
Among people with substance use disorders — a group already at high risk — GLP-1 drugs were associated with lower risk of suicidal ideation and attempts.
That supports findings from several newer studies.
Important Caveat
This study shows association, not proof.
Meaning:
The drugs might reduce addiction risk…
but they might also be linked to other factors that reduce risk.
Researchers tried to control for that by comparing two diabetes medications prescribed to similar patients.
But only randomized clinical trials can prove cause and effect.
Also: These Drugs Aren’t Risk-Free
GLP-1 medications can cause side effects, including:
• Nausea
• Vomiting
• Gallbladder disease
• Pancreatitis (rare)
So doctors aren’t about to start prescribing them just for addiction.
Not yet.
The Recap
The GLP-1 story keeps getting weirder.
First: diabetes drugs.
Then: blockbuster weight-loss medications.
Then: possible heart and brain benefits.
Now?
They might also reshape the brain’s reward system.
In this study of more than 600,000 patients, GLP-1 drugs were linked to:
• Lower risk of developing multiple addictions
• Fewer overdoses and hospitalizations
• Reduced suicide risk among people with addiction
If future clinical trials confirm the effect, these drugs could become something unexpected:
The first metabolic medications that also help treat addiction.
Which would make them less like weight-loss drugs…
…and more like a whole new class of brain-metabolism medicine.
Cai M, Choi T, Xie Y, Al-Aly Z. Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study. BMJ. 2026 Mar 4;392:e086886. doi: 10.1136/bmj-2025-086886. PMID: 41781010; PMCID: PMC12958796.
The Pharmers Almanac 